ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Vitamin D supplements, sleep could help manage pain

Bacopa: The Herb That May Increase Your Brain Power

Lilac Oil: More Than Just for Fragrance

Eat More Yogurt and Avoid Osteoporosis

Safflower: An Economically Important Herb That Can Benefit Humans and Animals Alike

What Is Bilberry Good For?

Coffee, herbal tea may help prevent liver fibrosis

Crafty Uses for Carrot Seed Oil

Resveratrol Improves Arteries

Higher omega 3 levels linked to improved brain blood flow

Print Page
Email Article

New Drug From Pfizer May Be an Option for FM Pain: Lyrica

  [ 1034 votes ]   [ Discuss This Article ] • January 17, 2005

New drug from Pfizer may be a blockbuster Firm to use Lyrica for nerve disorders BY KIM NORRIS
FREE PRESS BUSINESS WRITER A new drug with the potential of helping millions of people battle chronic nerve pain, epileptic seizures and, possibly anxiety disorder was developed in the Ann Arbor research facilities of giant pharmaceutical maker Pfizer Inc. Soon to be sold under the brand name Lyrica, for treating nerve pain, Pfizer's newest drug is expected to achieve at least $1 billion in sales, with the potential for much more if federal regulators approve more uses for the drug. The Ann Arbor research facility could be the incubator for future groundbreaking drugs that employ the unique characteristics of Lyrica to treat a broad range of illnesses and disorders, researchers hope. Pfizer received approval from the Food and Drug Administration Dec. 31 to market Lyrica in the United States for two uses: the nerve pain associated with diabetic neuropathy and pain that often accompanies shingles. But because of the way Lyrica works -- through the central nervous system -- it has a potentially broad spectrum of uses, some of which are still in the development stages, says Toni Hoover, a psychologist and vice president and development site head of Pfizer Global Research and Development in Ann Arbor. Hoover has been leading the development team on Lyrica since 1998. Hoover described the way Lyrica works as "like a blanket to dampen the highly excited nerve endings," that cause not only pain, but also seizures and psychiatric disorders such as anxiety. Hoover said Lyrica could be a potential treatment for the pain associated with fibromyalgia, for which there is no treatment, as well as spinal cord injuries. "And we're undertaking other studies to see if it can treat other kinds of pain as well as disorders, all from the theory that there are many things caused by excited nerve endings and can be treated through the central nervous system," Hoover said. How big Lyrica becomes depends in large part on how many uses it receives approval for. "It's definitely a blockbuster -- a billion-dollar product," said Trevor Polischuk, pharmaceutical analyst with money manager ObriMed Advisors. "Whether it will be a mega blockbuster -- a multibillion-dollar product is still open to question." Lyrica's approved applications for nerve pain alone can generate $1 billion in sales. Nearly half of the 18 million Americans with diabetes will develop some form of diabetic neuropathy and about 3 million diabetics will experience painful neuropathy, often described as burning, tingling, stabbing, and a pins-and-needles feeling in the feet, legs, hands or arms. An estimated 50,000 Americans develop nerve pain from shingles, which is a skin disease caused by reaction to the same virus that causes chicken pox. Currently, there is no drug on the market to treat those two most common causes of nerve pain. Pfizer's Neurontin, which recently lost its patent protection, opening the doors to generic competitors, is approved for use in treating epilepsy and the pain associated with shingles, but was never formally approved for additional uses. Lyrica is the next generation drug in the same class as Neurontin -- a class developed and controlled by Pfizer alone, called Alpha 2 Delta Ligands. More than 10 years in the making, Lyrica has been the purview almost entirely of Ann Arbor, first as the R&D labs of Parke-Davis then Warner-Lambert, then Pfizer, as each was swallowed by its successor. Lyrica was developed from a chemical acquired from Northwestern University in 1992. Hoover estimated close to 500 colleagues around the world have worked on the drug over the last 12 years, taking it from a chemical to a tested product that could be mass marketed worldwide, performing clinical studies and complying with arduous FDA application processes. Given the potential uses for the class of drugs, the Ann Arbor research facility, which employs 2,600, stands to be a critical location for future Pfizer products. "We found that with our experiences in trying to understand why Neurontin works we could apply to Lyrica," Hoover said. "Ann Arbor did all the work on Neurontin. We have a great deal of expertise in Michigan in the development in this class of agent." If Lyrica is ever to achieve mega blockbuster status, it needs to be approved for uses beyond the nerve pain treatment. Another proposed use for Lyrica -- to control epileptic seizures -- could be a $500-million market. But the most lucrative application for Lyrica -- because it has the widest potential consumer demand -- is as a treatment for general anxiety disorder, which could be a $2-billion market, Polischuk estimated. Approval to use Lyrica to treat epilepsy is pending with the FDA and could come soon. However, federal regulators declined to approve Lyrica for treating anxiety. Pfizer spokesman Rick Chambers said the company will sit down with the FDA to find out what its concerns are regarding the use of Lyrica in treating anxiety and remains hopeful it will get approval. Pfizer also was surprised when Lyrica was tagged by the federal Drug Enforcement Agency to be scheduled as a controlled substance, a designation that could impact Pfizer's ability to market the drug. "Based on our data collected in animal and human studies, we expect Lyrica to have a low potential for misuse or abuse," Chambers said. Lyrica could provide a needed shot in the arm to Pfizer, which has lost or is losing its patent monopoly on some of its biggest-selling drugs and dealing with declining sales in its blockbuster arthritis drug Celebrex following the removal of rival product, Vioxx, from the market. Source: Detroit Free Press

Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength FibroSleep™ Energy NADH™ 12.5mg

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

NAD+ Ignite with Niagen

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

Joint Aches May Have Met Their Match in Curcumin Joint Aches May Have Met Their Match in Curcumin
The Surprising Benefits of Probiotics - What You Didn't Know The Surprising Benefits of Probiotics - What You Didn't Know
Running on Empty? Fuel Up with NADH Running on Empty? Fuel Up with NADH
Breakthrough Form of Magnesium Enhances Memory and Cognitive Function Breakthrough Form of Magnesium Enhances Memory and Cognitive Function
Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map